Osteoporosis in men with chronic obstructive pulmonary disease. Utility of phalangeal densitometry (AccuDEXA) as a screening method

被引:2
作者
Casado, E. [1 ]
Larrosa, M. [1 ]
Naval, E. [2 ]
Gallego, M. [2 ]
Gomez, A. [1 ]
Domingo, C. [2 ]
Gratacos, J. [1 ]
机构
[1] Univ Autonoma Barcelona, Inst Univ Parc Tauli, Hosp Sabadell, Unidad Reumatol, Barcelona, Spain
[2] Univ Autonoma Barcelona, Inst Univ Parc Tauli, Hosp Sabadell, Serv Neumol, Barcelona, Spain
来源
REUMATOLOGIA CLINICA | 2005年 / 1卷 / 01期
关键词
Osteoporosis; COPD; Bone densitometry; Phalanx;
D O I
10.1016/S1699-258X(05)72706-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To analyze the prevalence of osteoporosis in men with chronic obstructive pulmonary disease (COPD) and to evaluate whether phalangeal densitometry (AccuDEXA) could be a useful screening method for identifying osteoporosis in these patients. Patients and methods: We performed a cross sectional study in male patients with COPD who were assessed by a pulmonologist in primary care and in our hospital as out-patients. The diagnosis of osteoporosis was established by conventional DEXA (lumbar spine and total hip), according to the WHO criteria. Bone mineral density (BMD) was assessed by AccuDEXA. We used a ROC curve to determine the best cut-off point for screening with this technique. Results: One hundred fifty male patients with COPD were included. The mean age was 67 +/- 3 years. The prevalence of osteoporosis by DEXA was 34%. BMD in phalanx was significantly correlated with BMD in lumbar spine and hip (r: 0.6). The sensitivity and specificity of AccuDEXA in identifying osteoporosis was 29% and 85%, respectively. The best cut-off point for AccuDEXA was a T-score of -0.8 (sensitivity 85%, specificity 63%, positive predictive value 56%, negative predictive value 89%). Glucocorticoid treatment and COPD severity were significantly associated with the presence of osteoporosis in these patients (p = 0.005 and p = 0.023 respectively). Conclusion: The prevalence of osteoporosis in men with COPD is high. This complication seems to be associated with glucocorticoid treatment and COPD severity. AccuDEXA could be a useful screening method for osteoporosis in these patients and could almost halve the number of conventional DEXAs performed.
引用
收藏
页码:7 / 11
页数:5
相关论文
共 18 条
[1]   Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the department of veterans affairs [J].
Adler, RA ;
Hochberg, MC .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (21) :2619-2624
[2]   Chronic obstructive pulmonary disease as a systemic disease: an epidemiological perspective [J].
Andreassen, H ;
Vestbo, J .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 :2S-4S
[3]   COPD and osteoporosis [J].
Biskobing, DM .
CHEST, 2002, 121 (02) :609-620
[4]   BONE-DENSITY AT VARIOUS SITES FOR PREDICTION OF HIP-FRACTURES [J].
CUMMINGS, SR ;
BLACK, DM ;
NEVITT, MC ;
BROWNER, W ;
CAULEY, J ;
ENSRUD, K ;
GENANT, HK ;
PALERMO, L ;
SCOTT, J ;
VOGT, TM .
LANCET, 1993, 341 (8837) :72-75
[5]   How can we treat or prevent corticosteroid-induced osteoporosis? [J].
Danés, I ;
Bosch, M .
MEDICINA CLINICA, 2003, 120 (12) :473-475
[6]   A comparative study of computed digital absorptiometry and conventional dual-energy X-ray absorptiometry in postmenopausal women [J].
Fiter, J ;
Nolla, JM ;
Gómez-Vaquero, C ;
Martínez-Aguilá, D ;
Valverde, J ;
Roig-Escofet, D .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (07) :565-569
[7]  
Ibanez R, 2004, REV ESP REUMATOL, V31, P419
[8]  
Ionescu AA, 2003, EUR RESPIR J, V22, p64S, DOI [10.1183/09031936.03.00004609, 10.4137/CCRPM.S22803]
[9]   Should COPD patients be routinely evaluated for bone mineral density? [J].
Karadag, F ;
Cildag, O ;
Yurekli, Y ;
Gurgey, O .
JOURNAL OF BONE AND MINERAL METABOLISM, 2003, 21 (04) :242-246
[10]  
Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785